Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis-Reference-Cited by-同舟云学术

Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis

Published:2014-05-27 Issue:1 Volume:60 Page:237-249
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Roh Yoon Seok¹²,Park Surim¹,Kim Jong Won¹,Lim Chae Woong¹,Seki Ekihiro²,Kim Bumseok¹

Affiliation:

1. Biosafety Research Institute and Laboratory of Pathology; College of Veterinary Medicine (BK21 Plus Program), Chonbuk National University; Jeonju South Korea

2. Department of Medicine; University of California, San Diego, School of Medicine; La Jolla CA USA

Funder

National Research Foundation of Korea (NRF)

NIH/NIDDK

Publisher

Wiley

Subject

Hepatology

Reference43 articles.

1. Liver fibrosis - from bench to bedside;Friedman;J Hepatol,2003

2. Liver fibrosis;Bataller;J Clin Invest,2005

3. Toll-like receptor signalling;Akira;Nat Rev Immunol,2004

4. Bacterial RNA is recognized by different sets of immunoreceptors;Eberle;Eur J Immunol,2009

5. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells;Mancuso;Nat Immunol,2009

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mouse Type-I Interferon-Mannosylated Albumin Fusion Protein for the Treatment of Chronic Hepatitis;Pharmaceuticals;2024-02-19

2. Gut microbiota in MAFLD: therapeutic and diagnostic implications;Therapeutic Advances in Endocrinology and Metabolism;2024-01

3. Integrating Network Pharmacology and Experimental Verification to Investigate the Mechanisms of Shuangshi Tonglin Capsule to Treat Chronic Prostatitis;Combinatorial Chemistry & High Throughput Screening;2023-08

4. Toll-like receptor-7 signaling in Kupffer cells exacerbates concanavalin A-induced liver injury in mice;International Immunopharmacology;2023-06

5. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease;Pharmacological Research;2022-11